Table of contents
From the editors
p379 | doi:10.1038/nrc2673
Research Highlights
Therapeutics: Selectively targeting turnover | PDF (176 KB)
p381 | doi:10.1038/nrc2666
Proteomics: Biomarkers on a nanoscale | PDF (211 KB)
p382 | doi:10.1038/nrc2659
Mouse Models: Closer than you think | PDF (149 KB)
p382 | doi:10.1038/nrc2662
In the news
An ounce of prevention? | PDF (98 KB)
p382 | doi:10.1038/nrc2671
In brief
Epigenetics | Metabolism | Biomarkers | Resistance | PDF (126 KB)
p383 | doi:10.1038/nrc2670
Metastasis: Attack of the mutant p53 | PDF (150 KB)
p384 | doi:10.1038/nrc2658
Tumour Suppressors: Multi-tasking | PDF (244 KB)
p384 | doi:10.1038/nrc2660
Melanoma: A more accurate diagnosis | PDF (240 KB)
p385 | doi:10.1038/nrc2661
Prostate cancer: Resistance is (hopefully) futile | PDF (119 KB)
p386 | doi:10.1038/nrc2668
Therapy: FGFR3 is key | PDF (126 KB)
p386 | doi:10.1038/nrc2669
Trial Watch
Personalized cocktails | Early warning | PDF (126 KB)
p386 | doi:10.1038/nrc2672
Genomics: A modular approach to signalling | PDF (200 KB)
p387 | doi:10.1038/nrc2667
Reviews
High-throughput insertional mutagenesis screens in mice to identify oncogenic networks
Jaap Kool & Anton Berns
p389 | doi:10.1038/nrc2647
Completion of the mouse genome sequence and improved technologies for cloning and sequencing of retroviral insertions have allowed researchers to address new questions about the genes and signalling networks involved in tumour development.
p21 in cancer: intricate networks and multiple activities
Tarek Abbas & Anindya Dutta
p400 | doi:10.1038/nrc2657
p21 has a well-known role in mediating p53-induced growth arrest. However, this protein can affect many other cellular functions and is activated independently of p53. What are the p53-independent roles of p21 in cancer, and could p21 be a therapeutic target?
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast, Jr, Bryan Hennessy & Gordon B. Mills
p415 | doi:10.1038/nrc2644
Ovarian cancer is a heterogeneous disease, making it difficult to provide standard regimens that are effective for all patients. Can increases in long-term survival be achieved by translating recent insights at the molecular and cellular levels into individual strategies for treatment and optimal early detection?
Cancer prevention by tea: animal studies, molecular mechanisms and human relevance
Chung S. Yang, Xin Wang, Gang Lu & Sonia C. Picinich
p429 | doi:10.1038/nrc2641
Extracts of tea, especially green tea, and tea polyphenols have been shown to inhibit the formation and development of tumours at different organ sites in animal models. How well are these data holding up in humans and what are the biological mechanisms of action?
Perspectives
Article series: MYC
Opinion
Facilitating replication under stress: an oncogenic function of MYC?
Steffi Herold, Barbara Herkert & Martin Eilers
p441 | doi:10.1038/nrc2640
Recent publications have indicated that the proto-oncogene MYC is closely involved in DNA replication and S phase checkpoint processes, and have suggested that limiting replication stress is a key function of this protein. How do these findings affect our understanding of how MYC transforms cells?
Opinion
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Stefan Löb, Alfred Königsrainer, Hans-Georg Rammensee, Gerhard Opelz & Peter Terness
p445 | doi:10.1038/nrc2639
Indoleamine-2,3-dioxygenase (IDO) is an immunosuppressive enzyme that is expressed in tumours and enables them to escape immunologically mediated rejection. However, we are far from understanding the biological relevance of IDO expression during tumorigenesis. We need a better understanding of IDO biology to provide a rationale for the use of IDO inhibitors in the clinic.
